Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study
Background Adherence to treatment is important in chronic dermatological diseases. There are limited data regarding the adherence to treatment in patients with psoriasis during the COVID‐19 pandemic. Aims We aimed to determine the rates of adherence to systemic treatments in patients with psoriasis...
Gespeichert in:
| Veröffentlicht in: | Journal of cosmetic dermatology 2022-01, Vol.21 (1), p.39-47 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 47 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | Journal of cosmetic dermatology |
| container_volume | 21 |
| creator | Oguz Topal, Ilteris Kara Polat, Asude Zindancı, İlkin Kıvanç Altunay, İlknur Akbulut, Tuğba Özkök Arıkan, Eylem Emel Topaloğlu Demir, Filiz Sivaz, Onur Karadağ, Ayşe Serap |
| description | Background
Adherence to treatment is important in chronic dermatological diseases. There are limited data regarding the adherence to treatment in patients with psoriasis during the COVID‐19 pandemic.
Aims
We aimed to determine the rates of adherence to systemic treatments in patients with psoriasis and to identify the causes of non‐adherence during the COVID‐19 pandemic.
Methods
We conducted a cross‐sectional multicenter study from May 2021 to August 2021. A questionnaire including items regarding sociodemographic characteristics of the patients, disease‐related characteristics, and treatment‐related characteristics were filled out by the physicians. The Psoriasis Area Severity Index (PASI), Hospital Anxiety, and Depression Scale, and the Dermatology Life Quality Index were calculated. The rate of adherence and non‐adherence to treatment and reasons for non‐adherence to treatment were examined.
Results
A total of 342 patients with psoriasis were included (182 male/160 female) in the study. The mean age of the patients was 45.9 ± 14.2 years. The average duration of psoriasis was 192 ± 134.7 months. While the rate of adherence to treatment was 57.6%, the rate of non‐adherence to treatment was 42.4%. There were no significant differences with respect to adherence to treatment in comparison with oral and injection‐therapy groups. The most frequent reasons for non‐adherence to treatment were inability to go to the hospital (19.2%), concern about the COVID‐19 infection (16.3%), discontinuation of the treatment by the doctor (13.7%), inability to reach the doctor (7.3%), and inability to have access to the medication (7.3%).
Conclusion
Adherence to oral and injection therapies was fairly high among our patients with psoriasis during the COVID‐19 pandemic. Psoriasis severity and duration of medication use had a negative impact on adherence to treatment. |
| doi_str_mv | 10.1111/jocd.14610 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8662046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2599073495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4480-83bb224d93ba34a5573b7082b6f5854105c83793d27193fa2e5a5a8586eaffe83</originalsourceid><addsrcrecordid>eNp9kctKxDAUhoMo3jc-gGQpwmiubeJCGMbbiDAbdRvSNnUivZmkSnc-gs_ok9g646Abszkh-c53DvwAHGB0gvtz-lyn2QlmEUZrYBuzmI4Ijvj66k7RFtjx_hkhHEvMN8EWZbEkgoltUIyzuXGmSg0MNfSdD6a0KQz9o246aCvY6GBNFTx8s2EOG187q731MGudrZ4GEk5mj9OLz_cPLHu6ygbDGRzDsi2CTfte46APbdbtgY1cF97sL-sueLi6vJ_cjO5m19PJ-G6UMibQSNAkIYRlkiaaMs15TJMYCZJEORecYcRTQWNJMxJjSXNNDNdcCy4io_PcCLoLzhfepk1Kkw0rOF2oxtlSu07V2qq_P5Wdq6f6VYkoIohFveBoKXD1S2t8UKX1qSkKXZm69YpwKVFMmeQ9erxAU1d770y-GoORGuJRQzzqO54ePvy92Ar9yaMH8AJ4s4Xp_lGp29nkYiH9Aj0UnNY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2599073495</pqid></control><display><type>article</type><title>Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Oguz Topal, Ilteris ; Kara Polat, Asude ; Zindancı, İlkin ; Kıvanç Altunay, İlknur ; Akbulut, Tuğba Özkök ; Arıkan, Eylem Emel ; Topaloğlu Demir, Filiz ; Sivaz, Onur ; Karadağ, Ayşe Serap</creator><creatorcontrib>Oguz Topal, Ilteris ; Kara Polat, Asude ; Zindancı, İlkin ; Kıvanç Altunay, İlknur ; Akbulut, Tuğba Özkök ; Arıkan, Eylem Emel ; Topaloğlu Demir, Filiz ; Sivaz, Onur ; Karadağ, Ayşe Serap</creatorcontrib><description>Background
Adherence to treatment is important in chronic dermatological diseases. There are limited data regarding the adherence to treatment in patients with psoriasis during the COVID‐19 pandemic.
Aims
We aimed to determine the rates of adherence to systemic treatments in patients with psoriasis and to identify the causes of non‐adherence during the COVID‐19 pandemic.
Methods
We conducted a cross‐sectional multicenter study from May 2021 to August 2021. A questionnaire including items regarding sociodemographic characteristics of the patients, disease‐related characteristics, and treatment‐related characteristics were filled out by the physicians. The Psoriasis Area Severity Index (PASI), Hospital Anxiety, and Depression Scale, and the Dermatology Life Quality Index were calculated. The rate of adherence and non‐adherence to treatment and reasons for non‐adherence to treatment were examined.
Results
A total of 342 patients with psoriasis were included (182 male/160 female) in the study. The mean age of the patients was 45.9 ± 14.2 years. The average duration of psoriasis was 192 ± 134.7 months. While the rate of adherence to treatment was 57.6%, the rate of non‐adherence to treatment was 42.4%. There were no significant differences with respect to adherence to treatment in comparison with oral and injection‐therapy groups. The most frequent reasons for non‐adherence to treatment were inability to go to the hospital (19.2%), concern about the COVID‐19 infection (16.3%), discontinuation of the treatment by the doctor (13.7%), inability to reach the doctor (7.3%), and inability to have access to the medication (7.3%).
Conclusion
Adherence to oral and injection therapies was fairly high among our patients with psoriasis during the COVID‐19 pandemic. Psoriasis severity and duration of medication use had a negative impact on adherence to treatment.</description><identifier>ISSN: 1473-2130</identifier><identifier>EISSN: 1473-2165</identifier><identifier>DOI: 10.1111/jocd.14610</identifier><identifier>PMID: 34792848</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>adherence ; Adult ; Covid ; COVID-19 ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Original ; Pandemics ; psoriasis ; Psoriasis - drug therapy ; Psoriasis - epidemiology ; Quality of Life ; SARS-CoV-2 ; Severity of Illness Index</subject><ispartof>Journal of cosmetic dermatology, 2022-01, Vol.21 (1), p.39-47</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4480-83bb224d93ba34a5573b7082b6f5854105c83793d27193fa2e5a5a8586eaffe83</citedby><cites>FETCH-LOGICAL-c4480-83bb224d93ba34a5573b7082b6f5854105c83793d27193fa2e5a5a8586eaffe83</cites><orcidid>0000-0001-8735-9806</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjocd.14610$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjocd.14610$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34792848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oguz Topal, Ilteris</creatorcontrib><creatorcontrib>Kara Polat, Asude</creatorcontrib><creatorcontrib>Zindancı, İlkin</creatorcontrib><creatorcontrib>Kıvanç Altunay, İlknur</creatorcontrib><creatorcontrib>Akbulut, Tuğba Özkök</creatorcontrib><creatorcontrib>Arıkan, Eylem Emel</creatorcontrib><creatorcontrib>Topaloğlu Demir, Filiz</creatorcontrib><creatorcontrib>Sivaz, Onur</creatorcontrib><creatorcontrib>Karadağ, Ayşe Serap</creatorcontrib><title>Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study</title><title>Journal of cosmetic dermatology</title><addtitle>J Cosmet Dermatol</addtitle><description>Background
Adherence to treatment is important in chronic dermatological diseases. There are limited data regarding the adherence to treatment in patients with psoriasis during the COVID‐19 pandemic.
Aims
We aimed to determine the rates of adherence to systemic treatments in patients with psoriasis and to identify the causes of non‐adherence during the COVID‐19 pandemic.
Methods
We conducted a cross‐sectional multicenter study from May 2021 to August 2021. A questionnaire including items regarding sociodemographic characteristics of the patients, disease‐related characteristics, and treatment‐related characteristics were filled out by the physicians. The Psoriasis Area Severity Index (PASI), Hospital Anxiety, and Depression Scale, and the Dermatology Life Quality Index were calculated. The rate of adherence and non‐adherence to treatment and reasons for non‐adherence to treatment were examined.
Results
A total of 342 patients with psoriasis were included (182 male/160 female) in the study. The mean age of the patients was 45.9 ± 14.2 years. The average duration of psoriasis was 192 ± 134.7 months. While the rate of adherence to treatment was 57.6%, the rate of non‐adherence to treatment was 42.4%. There were no significant differences with respect to adherence to treatment in comparison with oral and injection‐therapy groups. The most frequent reasons for non‐adherence to treatment were inability to go to the hospital (19.2%), concern about the COVID‐19 infection (16.3%), discontinuation of the treatment by the doctor (13.7%), inability to reach the doctor (7.3%), and inability to have access to the medication (7.3%).
Conclusion
Adherence to oral and injection therapies was fairly high among our patients with psoriasis during the COVID‐19 pandemic. Psoriasis severity and duration of medication use had a negative impact on adherence to treatment.</description><subject>adherence</subject><subject>Adult</subject><subject>Covid</subject><subject>COVID-19</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Pandemics</subject><subject>psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - epidemiology</subject><subject>Quality of Life</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><issn>1473-2130</issn><issn>1473-2165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctKxDAUhoMo3jc-gGQpwmiubeJCGMbbiDAbdRvSNnUivZmkSnc-gs_ok9g646Abszkh-c53DvwAHGB0gvtz-lyn2QlmEUZrYBuzmI4Ijvj66k7RFtjx_hkhHEvMN8EWZbEkgoltUIyzuXGmSg0MNfSdD6a0KQz9o246aCvY6GBNFTx8s2EOG187q731MGudrZ4GEk5mj9OLz_cPLHu6ygbDGRzDsi2CTfte46APbdbtgY1cF97sL-sueLi6vJ_cjO5m19PJ-G6UMibQSNAkIYRlkiaaMs15TJMYCZJEORecYcRTQWNJMxJjSXNNDNdcCy4io_PcCLoLzhfepk1Kkw0rOF2oxtlSu07V2qq_P5Wdq6f6VYkoIohFveBoKXD1S2t8UKX1qSkKXZm69YpwKVFMmeQ9erxAU1d770y-GoORGuJRQzzqO54ePvy92Ar9yaMH8AJ4s4Xp_lGp29nkYiH9Aj0UnNY</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Oguz Topal, Ilteris</creator><creator>Kara Polat, Asude</creator><creator>Zindancı, İlkin</creator><creator>Kıvanç Altunay, İlknur</creator><creator>Akbulut, Tuğba Özkök</creator><creator>Arıkan, Eylem Emel</creator><creator>Topaloğlu Demir, Filiz</creator><creator>Sivaz, Onur</creator><creator>Karadağ, Ayşe Serap</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8735-9806</orcidid></search><sort><creationdate>202201</creationdate><title>Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study</title><author>Oguz Topal, Ilteris ; Kara Polat, Asude ; Zindancı, İlkin ; Kıvanç Altunay, İlknur ; Akbulut, Tuğba Özkök ; Arıkan, Eylem Emel ; Topaloğlu Demir, Filiz ; Sivaz, Onur ; Karadağ, Ayşe Serap</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4480-83bb224d93ba34a5573b7082b6f5854105c83793d27193fa2e5a5a8586eaffe83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>adherence</topic><topic>Adult</topic><topic>Covid</topic><topic>COVID-19</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Pandemics</topic><topic>psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - epidemiology</topic><topic>Quality of Life</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oguz Topal, Ilteris</creatorcontrib><creatorcontrib>Kara Polat, Asude</creatorcontrib><creatorcontrib>Zindancı, İlkin</creatorcontrib><creatorcontrib>Kıvanç Altunay, İlknur</creatorcontrib><creatorcontrib>Akbulut, Tuğba Özkök</creatorcontrib><creatorcontrib>Arıkan, Eylem Emel</creatorcontrib><creatorcontrib>Topaloğlu Demir, Filiz</creatorcontrib><creatorcontrib>Sivaz, Onur</creatorcontrib><creatorcontrib>Karadağ, Ayşe Serap</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cosmetic dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oguz Topal, Ilteris</au><au>Kara Polat, Asude</au><au>Zindancı, İlkin</au><au>Kıvanç Altunay, İlknur</au><au>Akbulut, Tuğba Özkök</au><au>Arıkan, Eylem Emel</au><au>Topaloğlu Demir, Filiz</au><au>Sivaz, Onur</au><au>Karadağ, Ayşe Serap</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study</atitle><jtitle>Journal of cosmetic dermatology</jtitle><addtitle>J Cosmet Dermatol</addtitle><date>2022-01</date><risdate>2022</risdate><volume>21</volume><issue>1</issue><spage>39</spage><epage>47</epage><pages>39-47</pages><issn>1473-2130</issn><eissn>1473-2165</eissn><abstract>Background
Adherence to treatment is important in chronic dermatological diseases. There are limited data regarding the adherence to treatment in patients with psoriasis during the COVID‐19 pandemic.
Aims
We aimed to determine the rates of adherence to systemic treatments in patients with psoriasis and to identify the causes of non‐adherence during the COVID‐19 pandemic.
Methods
We conducted a cross‐sectional multicenter study from May 2021 to August 2021. A questionnaire including items regarding sociodemographic characteristics of the patients, disease‐related characteristics, and treatment‐related characteristics were filled out by the physicians. The Psoriasis Area Severity Index (PASI), Hospital Anxiety, and Depression Scale, and the Dermatology Life Quality Index were calculated. The rate of adherence and non‐adherence to treatment and reasons for non‐adherence to treatment were examined.
Results
A total of 342 patients with psoriasis were included (182 male/160 female) in the study. The mean age of the patients was 45.9 ± 14.2 years. The average duration of psoriasis was 192 ± 134.7 months. While the rate of adherence to treatment was 57.6%, the rate of non‐adherence to treatment was 42.4%. There were no significant differences with respect to adherence to treatment in comparison with oral and injection‐therapy groups. The most frequent reasons for non‐adherence to treatment were inability to go to the hospital (19.2%), concern about the COVID‐19 infection (16.3%), discontinuation of the treatment by the doctor (13.7%), inability to reach the doctor (7.3%), and inability to have access to the medication (7.3%).
Conclusion
Adherence to oral and injection therapies was fairly high among our patients with psoriasis during the COVID‐19 pandemic. Psoriasis severity and duration of medication use had a negative impact on adherence to treatment.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>34792848</pmid><doi>10.1111/jocd.14610</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8735-9806</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-2130 |
| ispartof | Journal of cosmetic dermatology, 2022-01, Vol.21 (1), p.39-47 |
| issn | 1473-2130 1473-2165 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8662046 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | adherence Adult Covid COVID-19 Cross-Sectional Studies Female Humans Male Middle Aged Original Pandemics psoriasis Psoriasis - drug therapy Psoriasis - epidemiology Quality of Life SARS-CoV-2 Severity of Illness Index |
| title | Adherence to systemic therapy in patients with psoriasis during the COVID‐19 pandemic: A multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20systemic%20therapy%20in%20patients%20with%20psoriasis%20during%20the%20COVID%E2%80%9019%20pandemic:%20A%20multicenter%20study&rft.jtitle=Journal%20of%20cosmetic%20dermatology&rft.au=Oguz%20Topal,%20Ilteris&rft.date=2022-01&rft.volume=21&rft.issue=1&rft.spage=39&rft.epage=47&rft.pages=39-47&rft.issn=1473-2130&rft.eissn=1473-2165&rft_id=info:doi/10.1111/jocd.14610&rft_dat=%3Cproquest_pubme%3E2599073495%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2599073495&rft_id=info:pmid/34792848&rfr_iscdi=true |